Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Marex Group Limited Ordinary Shares (MRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Marex Group Limited Ordinary Shares — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Marex Group Limited Ordinary Shares trades at $68.92 (market cap $5.18B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Marex Group Limited Ordinary Shares pays a 0.89% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Marex Group Limited Ordinary Shares for 3 Days on average.
| HNGE | MRX | |
|---|---|---|
Market Cap | $8.48B | $5.18B |
Volume | 879,799 | 794,309 |
Sector | Health | Financials |
52-Week High | $105.14 | $78.27 |
52-Week Low | $31.17 | $29.92 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $8.10B | $8.26B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
MRX trades at $71.95, down 0.47% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with a P/E of 14.62 and robust profitability, including a 9.69% net income margin and 27.57% ROE. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.64 surpassing the $1.36 estimate. Positive news includes record H1 2026 results and strategic developments in financial infrastructure.
The outlook for MRX is positive, supported by strong earnings momentum, a 100% buy rating from analysts, and a consensus price target of $83.67 implying significant upside. Key risks include execution of its acquisition strategy and market volatility. The stock's current valuation and growth trajectory present a compelling opportunity, though investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Marex Group Limited Ordinary Shares
Marex Group provides financial services across commodities, financial markets, and corporate clients. Its services include clearing, agency and execution, market making, hedging, and securities services.
Read more on MRX →
